abeta peptide sequence sequences - Amyloid beta 42sequence Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln

Amyloid beta molecular weight kDa The abeta peptide sequence is a critical determinant of its biological function and aggregation propensity, particularly in the context of Alzheimer's disease. This peptide, a key component of amyloid plaques, is derived from the amyloid precursor protein (APP) and exists in several forms, with the 40-amino acid (Aβ40) and 42-amino acid (Aβ42) variants being the most studiedSynthetic peptide chosen from human Abeta (1-42) protein. Amino acid sequence:D-A-E-F-R-H-D-S-G-Y-E-V-H-H-Q-K-L-V-F-F-A- .... Understanding the precise amino acid sequence of these peptides is fundamental to unraveling their role in neurodegeneration and developing potential therapeutic strategies.2025年5月16日—Here, we investigated the impact of exogenous amyloidsequencesderived from the gut microbiota on the heterotypic aggregation of Aβ peptides.

Understanding the Amyloid-Beta Peptide Sequences

Amyloid-beta (Aβ) peptides are a group of proteins generated through the proteolytic cleavage of the amyloid precursor protein (APP). While Aβ peptides can range from 36 to 43 amino acids, the most prevalent and biologically significant forms are Aβ40 and Aβ42. These variations in length, particularly the C-terminal truncation, significantly influence their aggregation behavior and pathogenicity.2025年5月16日—Here, we investigated the impact of exogenous amyloidsequencesderived from the gut microbiota on the heterotypic aggregation of Aβ peptides.

* Aβ40 Sequence: This 40-amino acid peptide is often considered the more soluble and less aggregation-prone form. Its sequence begins with aspartic acid (Asp) and ends with phenylalanine (Phe). A common representation of the Aβ40 sequence is:

Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val.作者：V Castelletto·2011·被引用次数：30—A series of heptapeptides comprising thecore sequence Aβ(16–20), KLVFF, of the amyloid β peptide coupled with paired N-terminal γ-amino acids are investigated

* Aβ42 Sequence: The Aβ42 peptide is characterized by the addition of two additional hydrophobic amino acids, glycine (Gly) and valine (Val), at the C-terminus, making it a 42-amino acid peptidePhysiological roles of amyloid-beta and implications for its removal in .... This longer sequence is more prone to aggregation and is strongly implicated in the pathogenesis of Alzheimer's diseaseFormula, C203H311N55O60S ; Sequence,DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA; Storage, Store at -20°C ; Purity, ≥95% (HPLC) ; CAS Number, 107761-42-2.. The sequence for Aβ42 builds upon the Aβ40 sequence:

Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala.3D structure of Alzheimer's amyloid-β(1–42) fibrils - PNAS

The primary amino acid sequence of Aβ42 is crucial because the extra two residues significantly alter its biophysical properties, promoting faster aggregation and the formation of more stable and toxic oligomeric species.

Key Features of the abeta Peptide Sequence

The sequence of the abeta peptide contains several notable features that contribute to its aggregation and biological activity:

* Hydrophobic Core: The sequence contains hydrophobic regions, particularly the KLVFF motif (residues 16-20), which is conserved across species and plays a critical role in mediating peptide-peptide interactions and driving the formation of beta-sheet structures characteristic of amyloid fibrils.Alzheimer's disease - Causes - NHS

* Charged Residues: The presence of charged amino acids, such as aspartic acid (negative charge) and histidine (can be positively charged at physiological pH), influences the peptide's solubility, aggregation kinetics, and interactions with cellular components.Alzheimer's disease - Causes - NHS

* C-terminal Variants: As mentioned, the presence or absence of the terminal Gly-Val residues in Aβ42 versus Aβ40 is a key differentiator.Beta-Amyloid (1-42) This difference in length is directly linked to the increased propensity of Aβ42 to aggregate and form toxic species, making the Aβ42 sequence particularly relevant in Alzheimer's disease research.

Significance in Alzheimer's Disease and Research

The aggregation of Aβ peptides, especially Aβ42, into insoluble fibrils is a hallmark pathological feature of Alzheimer's disease. These aggregates form amyloid plaques in the brain, which are associated with neuronal dysfunction and death.Amyloidogenic proteins (Abeta peptide) in Alzheimer's disease (AD) and alpha-synuclein (alpha-Syn) in Parkinson's disease (PD) are typically soluble monomeric ...

* Diagnostic Markers: The ratio of Aβ42 to Aβ40 in cerebrospinal fluid (CSF) is a key biomarker used in the diagnosis of Alzheimer's disease. An elevated Aβ42/Aβ40 ratio often indicates increased Aβ42 aggregation and deposition.

* Therapeutic Targets: The abeta peptide sequence itself, and its propensity to aggregate, are major targets for therapeutic interventions. Research is focused on developing antibodies that can clear Aβ plaques, small molecules that can inhibit Aβ aggregation, or strategies that can prevent its productionBeta-Amyloid (1-40) Peptide.

* Structural Studies: Understanding the three-dimensional structure of Aβ peptides, particularly in their aggregated forms (oligomers and fibrils), is essential for understanding their toxicity. Techniques like NMR and cryo-electron microscopy are used to elucidate these structures, providing insights into how the abeta peptide sequence dictates its self-assembly.

In summary, the abeta peptide sequence, particularly the distinct sequences of Aβ40 and Aβ42, is central to its role in neurological disorders like Alzheimer's disease. Research into these sequences provides critical insights into disease mechanisms and informs the development of diagnostic tools and therapeutic strategies.Amyloid beta peptide (1-42) - Alzheimer's disease